Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 |
| NCT02296996 | Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | completed | Phase 2 | 25 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01069627 | A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00027586 | Imatinib Mesylate in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00404235 | Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 76 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00861913 | Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01666418 | Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel | completed | Phase 2 | 19 | University of ZurichOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02272855 | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | completed | Phase 2 | 46 | Takara Bio Inc.INDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT02155322 | A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) | completed | Phase 2 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT01673854 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | completed | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01064713 | Phase II Study of Tesetaxel in Metastatic Melanoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT01174238 | A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | completed | Phase 2 | 40 | Adil DaudOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00383292 | A Study of Tasisulam in Treating Participants With Malignant Melanoma | completed | Phase 2 | 130 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 6, 2018 | clinicaltrials |
| NCT00804908 | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | completed | Phase 2 | 346 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | completed | Phase 2 | 20 | Catalysis SLINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01323517 | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00256282 | Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | completed | Phase 2 | 52 | John P. FruehaufOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT00938223 | Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma(MEL39) | completed | Phase 2 | 51 | Craig L Slingluff, JrOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT00626405 | Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 95 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT00101166 | Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma | completed | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 23 | University Hospital ErlangenOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | completed | Phase 1 / Phase 2 | 34 | Nina BhardwajOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01693068 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | completed | Phase 2 | 194 | EMD SeronoINDUSTRY | 14 | Jan 5, 2018 | clinicaltrials |
| NCT00726739 | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00387751 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00715793 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma(UPCI-07-008) | completed | Phase 1 / Phase 2 | 39 | Hussein TawbiOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01153763 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma | completed | Phase 2 | 92 | GlaxoSmithKlineINDUSTRY | 5 | Sep 27, 2017 | clinicaltrials |
| NCT00521001 | Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | completed | Phase 2 | 49 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01253564 | A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases | completed | Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00107718 | Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | completed | Phase 2 | 64 | GlaxoSmithKlineINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00949702 | A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 132 | Hoffmann-La RocheINDUSTRY | 2 | Jul 25, 2017 | clinicaltrials |
| NCT00434252 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma(BEAM) | completed | Phase 2 | 214 | Genentech, Inc.INDUSTRY | 0 | Jul 18, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00610857 | Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma | completed | Phase 2 | 37 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00397982 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma(Mel47) | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01676779 | mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma(DC-MEL) | completed | Phase 2 | 88 | Universitair Ziekenhuis BrusselOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00093119 | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma | completed | Phase 2 | 75 | CelgeneINDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2019source: clinicaltrials